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ABSTRACT 
Schizophrenia is characterized by early onset and chronic lapse in most of the patients. 
The suffering associated with schizophrenia is enormous – for patients, families, and in 
society at large. Pharmacotherapy is the mainstay of treatment, without which most 
psychosocial treatment would not be possible. However, substantial variety in efficacy as well 
as frequently reported side effects are problems often encountered with current antipsychotic 
treatment. Cytochrome P450 (CYP) enzymes are involved in the metabolism of most 
psychotropic drugs and characterized as the most important factor for individual variation to 
drug response.  
This study investigated pharmacotherapy of schizophrenic inpatients in seven different 
nursing homes receiving long-term antipsychotic treatment. Impact of environmental- and 
genetic factors on serum concentration of antipsychotics was studied. CYP-genotyping of 
isoenzymes CYP2C9, CYP2C19 and CYP2D6 were performed for both a patient group 
(n=109) and a control group (n=136). Clinical data were collected from records and medicine 
cards. Serum concentrations (trough) were obtained for all antipsychotics used by the patients.   
The patients were on average treated with 1.5 antipsychotics and 2.7 concomitant 
drugs. Our patient group received a total of 2.2 defined daily doses (DDD) of antipsychotics 
compared to an average of 1.2 DDD reported in a study of psychiatric hospital inpatients. The 
measured genotypes were not significantly different between the patient- and control group. 
Only one of the patients had been genotyped prior to the project. Patients being poor 
metabolizers had higher serum concentrations and patients being ultra rapid metabolizers had 
decreased serum concentrations from a given dose. CYP2D6 intermediate-metabolizer 
genotype appeared to be important in some patients, especially when other factors (e.g. 
environmental, polypharmacy) were present. Low doses of CYP2D6 inhibitors appeared to be 
of minor importance as long as it was the only factor influencing CYP activity. Use of CYP 
inducers led to decreased serum concentrations. Smoking did significantly decrease serum 
concentrations of CYP1A2 substrates and the induction seemed to be similar in heavy 
compared to light smokers.   
 Pharmacotherapy in patients suffering from chronic schizophrenia is characterized by 
polypharmacy and somewhat high doses of antipsychotics. Both genetic and environmental 
factors appear to influence the serum concentration. CYP-genotyping combined with 
therapeutic drug monitoring can be an important tool in individualization of drug regimes. 
Reassessing the pharmacotherapy of some of these patients might lead to an improvement of 
their current treatment.    
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1 INTRODUCTION 
1.1 Schizophrenia 
 
Schizophrenia is defined by World Health Organization (WHO): “A severe emotional 
disorder of psychotic depth characteristically marked by a retreat from reality with delusion 
formation, hallucinations, emotional disharmony, and regressive behaviour”.   
 
The essential features of schizophrenia are a mixture of characteristic signs associated with 
marked social and or occupational dysfunction. The condition is not caused by direct 
physiological effects of a substance or a general medical condition. The characteristic 
symptoms involve a range of cognitive and emotional dysfunctions: Perception, language and 
communication, drive, affect, attention, behavioural monitoring and fluency and productivity 
of thought and speech. No single symptom is equivalent with schizophrenia; the diagnosis 
involves the recognition of a constellation of signs and symptoms associated with impaired 
occupational or social functioning. These can be divided into two broad categories – positive 
symptoms (excess normal functions) and negative symptoms (loss of normal functions). 
Positive symptoms include delusions, hallucinations, behavioural, language and 
communication problems. Negative symptoms include social withdrawal, emotional flattening 
and reduced body language, eye contact and responsiveness. Negative symptoms are more 
difficult to diagnose. It requires observation of the patient over time and preferably a 
description of resent changes in personality by relatives. 
 
Schizophrenia tends to develop between the ages of 16 and 30 years, and mostly persists 
throughout the patient’s lifetime. Women tend to have a later onset than men. The illness 
shows a lifetime prevalence of about 1% in the general population (Mueser and McGurk). 
According to WHO, schizophrenia is the fifth most disabling disease worldwide. 10% of all 
disabled citizens in Norway have schizophrenia, and the overall cost per year for 
schizophrenia is estimated to 4 billion Norwegian kroner (NOK) (1995) (Johannessen). The 
costs for drug treatment of schizophrenia have been increasing the last years and were 370 
million NOK in 2003 (Fig 1-1) (Norwegian Institute of Public Health). 
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Fig 1-1: Annual costs of antipsychotic drugs in Norway in NOK (millions) 
 
The human suffering associated with schizophrenia is enormous – for patients, families, and 
in society at large. In western countries costs are estimated to exceed 1% of the national 
budget. There is no other disorder with comparable costs. Schizophrenia alone costs more 
than all types of cancer and more than all cardiovascular diseases (Johannessen). 
 
There are reasons to believe that not all patients with schizophrenia are given treatment in 
accordance with good clinical practice. The lag time from onset of manifest psychosis and to 
appropriate treatment is often long, in western countries up to 2-3 years (Melle et al.).  Early 
detection and treatment of schizophrenia is an important challenge. Optimal management of 
the disease includes psychological, social and occupational therapies. Psychosocial 
intervention seeks to improve the management of the disorder (e.g. coping with symptoms, 
relapse prevention) and enhance functioning in areas such as independent living, relationships 
and work. Pharmacotherapy is the mainstay of treatment, without which most psychosocial 
treatment would not be possible.   
1.2 Pharmacotherapy of schizophrenia 
 
The first antipsychotics were developed more than 50 years ago. Introduction of 
chlorpromazine in 1952 opened possibilities to de-institutionalize psychotic patients. The 
antipsychotics are divided in two groups: the first-generation antipsychotics also termed 
typical, and the second-generation antipsychotics termed atypical.  Pharmacological receptor 
binding profile is the main difference between the two groups. Examples of marketed 
antipsychotics are provided in table 1-1. 
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1.2.1 Typical antipsychotics 
 
The typical antipsychotics are characterized by high in vitro binding affinities for the 
dopamine D2 receptor. They have good antipsychotic effect, but their use is limited by 
common and sometimes severe side effects. This includes extrapyramidal effects like 
akathisia, rigidity and tardive dyskinesia, but also sedation (Freedman). There are two 
subgroups of typical antipsychotics; the high potency (low dosed <30 mg daily) and the low 
potency (high dosed >100 mg daily). The potency in binding affinities for the dopamine 
receptor separates the two groups.  
1.2.2 Atypical antipsychotics 
 
Clozapine was reintroduced in the late 1980s as a prototype for the atypical antipsychotics, 
and has led to significant advances in the pharmacological management for schizophrenia. 
This pharmacological progress has been attributed to 5-HT2A-antagonism and a diverse 
binding profile on several receptors in the CNS (e.g. serotonergic, dopaminergic, 
histaminergic, adrenergic and cholinergic receptors). Atypical antipsychotics are also superior 
to typical antipsychotics in improving cognitive functioning and negative symptoms, an 
important factor in treatment of schizophrenia (Mori et al.). The other atypical antipsychotics 
have been pharmacologically modelled, to a certain extent, after clozapine; the common 
feature being a strong 5-HT2A-antagonist. Atypical antipsychotics are better tolerated than the 
typical, but some of the atypical substances may still induce side effects like weight gain, 
sedation and metabolic complications (e.g. diabetes mellitus). It is clear that weight gain can 
undermine compliance, and may also lead to significant psychological distress and medical 
morbidity and mortality. A poor response to treatment is still considered a problem in 
schizophrenic patients. Loss of clinical efficacy may be caused by interindividual differences 
in enzyme systems and drug metabolism. In spite of increased use and introduction of new 
atypical antipsychotics the last years, typical antipsychotics are still commonly prescribed.  
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Table 1-1: The typical and atypical antipsychotics prescribed to patients in this project: 
 
TYPICAL ANTIPSYCHOTICS ATYPICAL ANTIPSYCHOTICS 
Haloperidol (Haldol®) Clozapine (Leponex®) 
Zuclopenthixol (Cisordinol®) Olanzapine (Zyprexa®) 
Perphenazine (Trilafon®) Risperidone (Risperdal®) 
Flupentixol (Fluanxol®) Quetiapine (Seroquel®) 
Levomepromazine (Nozinan®) Amisulpride (Solian®) 
Thioridazine (Melleril®) Ziprasidon (Seldox®) 
Chlorprothixene (Truxal®)  
 
Relapse rates during two-year studies are shown to be approximately 30% during treatment 
with first generation antipsychotics and 80% without treatment (Marder et al.). The relapse 
rates are also shown to be different between first- and second-generation antipsychotics. In a 
one-year, multisite study by Csernansky et al. patients taking the second-generation drug 
risperidone had 25% relapse, as compared with a rate of 40% for patients taking the first-
generation drug haloperidol (Csernansky, Mahmoud and Brenner). 
 
1.2.3 Norwegian guidelines for the use of antipsychotics 
 
Patients being hospitalized for first episode of schizophrenia should preferably be drug free 
for two weeks or until diagnose is established. This is to ensure an adequate observational 
period to establish the correct diagnose and treatment. Norwegian guidelines suggest 
monotherapy for the treatment of schizophrenia. Initial doses should be low, and long term 
dosing should be kept at a minimum level if possible. Benzodiazepines can temporarily be 
used to treat anxiety, restlessness and disturbed sleep. Health care personnel should be aware 
of side effects and adverse drug reactions (Statens Helsetilsyn.). 
 
After the first episode of schizophrenia pharmacologic treatment should be maintained for at 
least two years. Patients with more than one episode of schizophrenia should receive 
antipsychotic treatment for at least 5 years. Patients that show relapse, suicidal attempts or 
violent and aggressive behaviour should receive treatment for more than five years, in most 
cases life-long treatment (Statens Helsetilsyn.). 
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1.2.4 Use of antipsychotics in Norway 
 
Consumption of antipsychotics in defined daily doses (DDD) showed a decreasing trend 
during the 1990s. The patients in psychiatric hospitals received 1.49 DDD antipsychotics in 
1991 and 1.22 DDD in 2000, a 19 % decrease. Since 2000 the consumption has been growing. 
The use of atypical drugs has shown a steady increase, from 7% in 1990 to 53% of totally 
prescribed antipsychotics in 2000 (Rytter and Haberg).  
1.3 Metabolism of antipsychotics 
 
Most lipophilic compounds such as psychotropics need to be metabolized prior to excretion in 
the urine. Lipophilic drugs are converted into more hydrophilic, usually less active or inactive 
metabolites. Drug metabolic reactions may be divided in two categories; phase I and phase II. 
Phase I involves modifications such as oxidation, dealkylation, hydrolysis and reduction. 
Phase II metabolism involves conjugation of glucoronide or sulphate to the parent drug or its 
phase I metabolites. Genetic and environmental factors heavily influence drug response. The 
efficacy of antipsychotic drug therapy is still difficult to predict in the individual, despite of 
the increasing recognition of possible pathological factors involved in schizophrenia. Genetic 
variability exists both at receptor, drug transporter and metabolism level. Genetic differences 
in the activity of metabolizing enzymes have been shown to be the most important source of 
variability in drug response. Phase I enzyme system cytochrome P450 (CYP) are responsible 
for metabolism of most of the typical and atypical antipsychotics.  
1.3.1 Cytochrome P450 monooxygenase 
 
CYP is a superfamily of phase I enzymes responsible for metabolism of many drugs and 
xenobiotics in the human body. They are haeme containing and derived their name from their 
absorption of light at 450 nm. The CYP superfamily is responsible for 70-80% of all phase I 
dependent metabolism, and are estimated to be involved in metabolism of more than 50% of 
clinically used drugs (Bertz and Granneman); (Evans and Relling). The vast majority of 
psychotropic drugs are metabolized by CYP, which makes CYP an important contributor to 
variability in psychiatric drug treatment. CYP enzymes are mainly localized in the 
endoplasmatic reticulum of liver cells, but also in the intestine and lungs.  
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More than 30 different subtypes are identified in humans, and they are categorized and named 
after homology of the amino acid sequence. See fig 1-2. Families share 40% homology (e.g. 
CYP2), subfamilies share 60% homology (e.g. CYP2D) and the subfamilies are divided into 
isoenzymes designated by an Arabic number (e.g. CYP2D6) (Rogers, Nafziger and Bertino, 
Jr.).   
 
Fig 1-2: Grouping and nomenclature of the CYP450 superfamily 
 
More than 30 CYP isoenzyme systems are characterized, but only a few of them are important 
in the metabolism of drugs. CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 are the far 
most abundant isoenzymes. Responsible for more than 90% of all CYP mediated drug 
metabolism (Fig 1-3) (Bertz and Granneman). 
 
1.4 Genetic differences of CYP activity  
 
The activity of the different CYP-enzymes shows great intra- and interindividual variation, 
due to both environmental and genetic factors. Genes that exist in different variants, because 
of evolutionary mutations, are termed polymorphic. Polymorphism refers to a genetic variant 
of a gene that occurs in more than 1% of a population. Genetic polymorphism is well 
described for isoenzymes CYP2C9, CYP2C19 and CYP2D6 (Ingelman-Sundberg). 
 
 
CYP
Family: CYP1 Family: CYP2 Famlily: CYP3 
Subfamily: CYP1A 
Isoenzym: CYP1A2 
Subfamily: CYP2C 
Isoenzyme:CYP2C19 Isoenzyme:CYP2C9
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Genetic variability will derive not only from genotype in the translated gene regions, but also 
from variability in gene expression and regulation. Environmental factors like cigarette 
smoke, certain drugs and foods can influence CYP-activity. CYP1A2 and CYP3A4 are 
important isoenzymes, responsible for more than 50% of CYP mediated metabolism. See fig. 
1-3. None of them exhibit genetic polymorphism, but both of them are highly influenced by 
environmental factors.   
 
There are different ways of obtain information about a persons CYP activity. A CYP 
genotyping will provide information about the subject’s genetic status, valid for the rest of the 
life. CYP-genotyping is currently performed by polymerase chain reaction (PCR); this 
technique is used to synthesize large quantities of specific DNA fragments. By DNA- 
synthesis, subsequent specific restriction enzyme digestion and separation of the DNA 
fragments it is possible to analyse for mutations and variants of genes. In this project 
mutations of isoenzymes CYP2C9, CYP2C19 and CYP2D6 are studied.   
 
CY2D6
20 %
CYP3A4
50 %
Other
5 %
CYP2C9
10 %
CYP2C19
15 %
 
Fig 1-3: Fractional share, in total CYP activity, of different isoenzymes. 
CYP2C9, CYP2C19 and CYP2D6 exhibit genetic polymorphism (Ingelman-Sundberg) 
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1.4.1 Genetic polymorphism 
 
Mutations in the CYP genes might lead to abolished, decreased or increased activity of the 
different isoenzymes. Abolished enzyme activity is commonly seen where both genes has 
been deleted, but has also its origin in mutations causing altered splicing, stop codons, 
abolished transcriptional start sites and deleterious amino acid changes. Mutations in substrate 
recognition sites (SRS) can cause the synthesis of enzymes with altered substrate specificity. 
Amino acid changes might lead to changes in protein folding and thereby altered specificity 
of the SRS.  Mutations of the different enzymes are named chronologically as they are 
identified, with a star (*) and an Arabic number. Reference variants (the first one detected) are 
termed *1, different mutations are then named *2, *3 etc. For practical reasons *1 will be 
used to designate all other gene variants than those analysed for in this project (wild type).  
1.4.2 Polymorphic isoenzymes  
 
CYP2C9 enzymes are responsible for 10% of total CYP mediated metabolism. Important 2C9 
substrates are NSAIDS, warfarin and phenytoine. This isoenzyme is not responsible for 
metabolism of any antipsychotic drugs. Three mutations were screened in this project: 
CYP2C9 *2, *3 and *5. All of them code for lower effect, but the impact of a *2 mutation is 
limited.  
 
CYP2C19 enzymes are responsible for 15% of total CYP mediated metabolism. Important 
2C19 substrates are tricyclic antidepressive drugs (TCA), benzodiazepines, antiepileptics, 
citalopram, moclobemide and omeprazole. This isoenzyme is not responsible for metabolism 
of any antipsychotic drugs. Four mutations were screened in this project: CYP2C19 *2, *3, *4 
and *5. *2 and *3 code for defect enzyme, *4 and *5 code for no enzyme production.  
 
CYP2D6 enzymes are responsible for 20% of total CYP mediated metabolism. It is involved 
in metabolism of seven of the fifteen antipsychotic drugs marketed in Norway (haloperidol, 
risperidone, zuclopenthixol, levomepromazine, perphenazine, chlorprothixene, flupenthixole). 
Three antipsychotics (perphenazine, levomepromazine and thioridazine) are reported to act as 
inhibitors on CYP2D6 metabolism (Ieiri et al.). CYP2D6 are not induced by any known 
substance. A small group of northern European Caucasians show a high activity in the 
CYP2D6 activity due to duplication of the CYP2D6 gene.  
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1.4.3 Genotypes 
 
Evolutionary mutations in the genes exist in a population, causing some genes to be altered or 
defect. The human genetic code is diploid, i.e. every person carries two sets of every gene. A 
person may therefore carry two, one or no functional sets of a gene. For isoenzyme CYP2D6 
one of the mutations code for a duplication of the gene. In this case it is possible to carry more 
than two active genes coding for functional CYP2D6 enzyme, a situation only described for 
CYP2D6. A population can be divided into 4 different subgroups reflecting the number of 
functional genes coding for an isoenzyme: 
 
No functional genes: Poor metabolizer (PM). This group is also termed homozygote 
positive for a non functional mutation (e.g. homozygote CYP2D6 *5 / *5).   
   
One functional gene: Intermediate metabolizer (IM). Persons with one normal and one 
defect copy of a gene are referred to as IM. A mutation in one of the gene copies is not always 
clinically relevant. IM are also termed heterozygote positive for a given mutation (e.g. 
CYP2D6 *1 / *4).   
 
Two functional genes: Extensive metabolizer (EM). This is the normal (wild type), both 
gene copies code for functional enzyme. (e.g. CYP2D6 *1 / *1). 
 
More than two functional genes: Ultra rapid metabolizer (UM). This genotype exists only 
for the CYP2D6 isoenzyme, where the *2 mutation code for a duplication of the gene. No 
exact cut-off point, however, exists or has been defined for the UM-group. This is partly 
explained by different number of functional gene copies (up to 13 copies have been described 
(Dalen et al.)) and because different methods are used to measure enzyme activity. 
 
Table 2-1 describes the mechanism of all the different CYP mutations tested in this project.  
 
 
The classification based on number of active genes, is used primarily to describe CYP2D6 
genotype. The system is also applicable to the other isoenzymes. PM genotype results in lack 
of metabolic capacity, increased exposure of parent drug or decreased exposure of active 
metabolites. Relevance of IM genotype will range from very low metabolic capacity, to 
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normal activity. UM will have extraordinary high metabolic capacity. Subjects that are PM or 
UM are more prone to drug levels outside the therapeutic range, loss of effect or increased 
risk of adverse drug reactions (ADR).   
 
1.4.4 Ethnical differences of CYP genoptype 
 
The occurrence of mutations in CYP-isoenzymes shows great variation between different 
ethnic groups. There are also differences between subpopulations within the same ethnic 
group (e.g. Caucasians). Frequencies of multi-duplicated CYP2D6-genes is about 1-2% in 
Swedish Caucasians, 3,6% in Germany, 7-10% in Spain and 10% on Sicily in Italy. In 
contrast the frequency is as high as 20% in Saudi Arabians and 29% in black Ethiopians 
(Bertilsson et al.). 
1.5 Environmental changes of CYP activity 
 
Drug metabolism may be changed by alteration of enzymatic functions by certain drugs, 
environmental chemicals (e.g. cigarette smoke) or foods.  
1.5.1 Inhibition and induction by drugs 
 
Drugs can act both as inhibitors or inducers of CYP activity. An inhibition might cause the 
patient to become a functional PM. All isoenzymes except for CYP2D6 are inducible by other 
drugs, causing increased CYP activity. Drug to drug interactions are a potential problem, 
because of inhibition and induction, when polytherapy is applied. Concomitant use of 
antiepileptics and antidepressants are potential causes for pharmacokinetic drug interactions 
in this group of patients. Concomitant use of CYP inhibitors might cause extensive 
metabolizers to exhibit poor metabolizer phenotype. 
1.5.2 Cigarette smoking 
 
Polycyclic aromatic hydrocarbons (PAH) from cigarette smoke are potent inducers of 
isoenzyme CYP1A2 (van der Steijns and van Weelden). This isoenzyme is responsible for 
most of the CYP450 metabolism of both clozapine and olanzapine, both commonly used in 
the treatment of schizophrenia. Studies indicate that approximately 70-80% of patients with 
schizophrenia smoke, compared to 28% of the general population (Statistics Norway). 
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1.6 Prediction and monitoring of drug response  
 
Polymorphism of clinical significance for pharmacological treatment can be identified by 
CYP-genotyping. However enzymes like CYP1A2 and CYP3A4 does not exhibit 
polymorphism. They require phenotyping or systematic use of therapeutic drug monitoring to 
estimate enzyme activity. Phenotyping is sensible for environmental- as well as genetic 
factors and provides information of the patient’s CYP-status at the time of phenotyping. 
Genotyping or phenotyping may indicate the response to a substance, and may identify 
possible pitfalls in pharmacological treatment. It can contribute to an optimal drug regime and 
confirm or support decisions based on TDM-data.  
1.7 Therapeutic drug monitoring 
 
Response to pharmacological treatment depends on a range of factors, including 
pharmacokinetic and pharmacodynamic differences. Serum concentrations after 
administration of a set dose can vary 10-20 times, in some cases up to 100 times (Bengtsson). 
For all the antipsychotics there are established a reference range of serum concentrations, but 
a therapeutic window is not defined for all atypical antipsychotics. Clinical practice is often 
based on subjective assessments of efficacy and side effects. Even atypical antipsychotics 
may produce side effects that resemble symptoms of the disease. TDM is important in 
establishment of new treatment, but also when changes in patient response occur. TDM might 
reveal zero amount of drug in the body (e.g. complete non-compliance), serum concentrations 
lower than expected (e.g. defects in absorption, non-compliance or increased clearance) to 
extremely high concentrations (e.g. overdosing, decreased clearance or drug-drug 
interactions). Several measures of through concentrations, over a period of time, will provide 
further information to guide therapy of the patient.  
 
Basis/reasons for performing TDM in psychiatric patients: 
-patients not responding to pharmacological treatment as expected 
-patients in need of long term treatment 
-narrow therapeutic index of drug  
-subjects with deviation in pharmacokinetics or -dynamics due to age, or somatic conditions 
-polypharmacy, drug-drug interactions, use of enzyme inhibitors or inducers 
-prior and after changes in drug regime 
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1.8 Aim of study 
 
The aim of this study was to investigate the use of psychotropics in schizophrenic patients 
living in nursing homes. Further, we wanted to study the impact of genetic and environmental 
factors on systemic serum concentrations of antipsychotics in this group of patients.  
 
The following questions will be addressed: 
 
What kind of pharmacological strategies are used in this population of psychiatric inpatients 
on long-term psychotropic treatment?  
What is the frequency of poor- and ultra rapid metabolizers in this patient group compared to 
a Norwegian Caucasian control group? 
How do CYP-mutations influence the serum concentrations in this group of patients? 
How do drug-drug interactions (polypharmacy) influence the serum concentrations of 
antipsychotics in this group of patients?  
How does cigarette smoking as well as daily consumption of cigarettes influence the serum 
concentrations in this group of patients? 
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2 METHODS 
2.1 Recruiting patients 
 
The project was initiated in 2003 by Dr. Per Håkon Eikeseth, Vor Frue Hospital. Application 
to the regional ethic committee was submitted by August 2003, and approved 22nd September 
2003 by the Regional Ethics Committee of Health Region 1 (Ref number: 410-03139) 
 
All patients recruited were living in nursing homes in the Oslo area. They all received long-
term treatment with antipsychotic medication and were considered to be stable in respect to 
both their medical condition and drug regime. The patients were all previously diagnosed with 
severe mental illnesses.  
 
A short interview was carried out to collect informed consent from the patients. Patient 
information was collected from records and medicine cards. The standard form from 
Department of Psychopharmacology was filled out to collect most of the patient information.   
2.1.1 Collected patient information 
 
Following patient information were collected:  
-date of birth, gender  
-onset and duration of psychiatric disease  
-height & weight  
-Body Mass Index 
Defined with the formula: ((height - cm) / (weight-kg x weight-kg)).  
BMI <18 is considered underweight 
BMI 18-27 is normal  
BMI 27-29.9 is overweight  
BMI score over 30 is considered obesity. 
-smoking behaviour  
-information regarding use and dosage of antipsychotic- and concomitant medication   
-Only drugs that were used on a regular basis were included 
-Only three concomitant substances were registered, but in addition the total number 
of concomitant substances is registered 
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-duration of current antipsychotic drug regime and time since last change of dosing or 
antipsychotic regime (in months).   
-time since administration of last dose of each antipsychotic 
-blood samples for obtaining CYP-genotype and serum concentrations of antipsychotics  
2.1.2 Study design 
 
Inclusion criteria:  
-ICD-10 F20.0-F39.0  (*) 
-Caucasian  
-Inpatient  
-Treated voluntarily with antipsychotic medication 
-Capable of understanding and signing the informed consent 
-Stable antipsychotic drug regime, no changes of dosing or substances within the last 28 days. 
* = a few of the patients had diagnoses other than schizophrenia 
 
Exclusion criteria:  
-Current drug abuse 
-Current alcohol abuse 
-Recent acute episode of psychiatric disease 
-Somatic diseases causing altered renal or hepatic metabolic capacities. 
2.2 Patient population 
 
The population consisted of 109 inpatients from different psychiatric nursing homes around 
Oslo. All ICD-10 diagnoses from F20.0-F39.0 were allowed, but most of the patients (n=90) 
fulfilled the criteria for schizophrenia (F20.0-F20.9). Each subject signed an informed written 
consent in order to participate in the study. 
       
Study nurses collected two vials of venous blood from each patient. Blood samples were 
collected to measure serum levels (trough) of all antipsychotics and to determine CYP- 
genotype. The vial of whole blood for genotyping (PCR) contained EDTA to prevent clotting. 
The vial for TDM was allowed to clot for 30 minutes before centrifugation and decantation of 
serum. Vials and form were immediately marked with analysis-number and patient initials.    
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2.3 Control group 
 
To compare the frequencies of CYP-mutations in the general Caucasian Norwegian 
population, a control group was established. The control group consisted of 136 volunteers, 
recruited from health care personnel and students at the University of Oslo. All signed an 
informed written consent. Information from the control group only included date of birth and 
gender. One vial of venous blood containing EDTA was collected from each member of the 
control group.  
2.4 Analytical methods 
 
Analysis of antipsychotic serum levels by HPLC-MS/MS 
 
Blood samples were analysed at the Department of Psychopharmacology, Diakonhjemmet 
Hospital Oslo. The separation and quantification (of all antipsychotics) was achieved using 
high-performance liquid chromatography (HPLC), mass spectrometry (MS). The LC-MS/MS 
system consisted of Waters 2695 Liquid Chromatograph (Milford, MA, USA), and mass 
spectrometric detection was carried out using Micromass Quattro micro  (Milford, MA, 
USA) operating in the positive electro-spray mode (AP-ESI).   
 
All analytical methods are performed in accordance with the quality handbook of Department 
of Psychopharmacology, Diakonhjemmet Sykehus.  
2.4.1 Sample preparation and analysis of blood samples 
 
Blood samples were allowed to clot for 30 minutes, centrifuged and transferred to new vials 
as serum. The sample preparation was performed with two different methods: Liquid-liquid 
extraction (LLE) and protein precipitation. All antipsychotic drugs are analysed with same 
equipment and analytical procedures, but in three groups based on time of retention:  
 
-Mass spectrometry run 1 (MS1) - protein precipitation: Olanzapine and chlorprothixene 
-Mass spectrometry run 2 (MS2) - liquid-liquid extraction: Amisulpride, risperidone, 
clozapine, haloperidol, levomepromazine 
-Mass spectrometry run 3 (MS3) - liquid-liquid extraction: Quetiapine, ziprasidone, 
chlorpromazine, zuclopenthixol, flupenthixole 
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2.4.2 Protein precipitation 
 
To 500µl serum the following chemicals were added:  
600µl Acetonitrile: Methanol (90:10). This solution also contained 0,5 µl promazine 1mM 
(internal standard). All samples were mixed 15 seconds on whirl-mixer and then cooled down 
for 10 minutes (-20ºC). The samples were centrifuged for 10 minutes. 200µl of the 
supernatant were transferred to new vials, corked with a septum and placed in an autosampler. 
2.4.3 Liquid-liquid extraction  
 
Minimum 1 ml of serum was required.  
The following chemicals were added to 1 ml serum:  
-120 µl 1,0M NaOH and 50 µl 20µM, promazine (internal standard).  
-3 ml isopropylamine, hexan 0.1:99.9 
-2 ml isopropylamine, etylacetate 0.1:99.9  
All vials were extracted 10 minutes on rotating mixer at 20 RPM and then centrifuged 10 
minutes at 3500 RPM. Samples were placed in -80ºC for 6-7 minutes to allow the water phase 
to freeze. The organic phase were transferred to new vials, heated to 37-40ºC and dried under 
a flow of nitrogen gas for 25 minutes. Samples were re-dissolved in mobile phase: 200µl 
acetonitrile, 10mM ammoniumacetate pH 4.5 (30:70). The samples were vortex mixed for 5 
minutes and placed in autosampler to be analysed.  
2.4.4 Quality controls 
 
Every run was set up with the following quality controls (control samples 2 through 8 went 
through the same sample preparation as the patient samples): 
1) Blank mobile phase 
2) Drug free serum (blank) 
3-6) Standards (prepared by adding 50 µl stock solution to 450µl blank serum) these four 
samples contain different concentrations of every antipsychotic included in the run. Results 
are used to obtain a standard curve.  
7) Control: low range. Blank serum spiked with an exact low concentration of every 
antipsychotic in the run.  
8) Control: high range. Blank serum spiked with an exact high concentration of every 
antipsychotic in the run.   
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2.4.5 Analysis and identification 
 
The separation was performed on an ACE 3AQ column, C8/C18 (100 x 2.1 mm, 5 µm), 
protected by an ACE 3AQ guard column (15 x 2.1 mm), both from TechnoLab. Time of 
retention and mass of the molecule ion was used for identification. Peak area was used for 
quantification by relating peak ratio [area drug/ area internal standard] to the peak ratio of the 
standard curves.  
2.4.6 Precision of the analytical results 
 
Precision was monitored as described in the quality handbook of the Department of 
Psychopharmacology. Coefficient of variation (CV) are recorded for all analyses on a regular 
basis, and denoted in percent. The CV was determined from the actual results of the high and 
low controls. CV are also known as the relative standard deviation and obtained by the 
following formula: 100 x standard deviation / mean. Values from the period when all blood 
samples were analysed were recorded. CV values for analytical procedures of all 
antipsychotics averaged 6.9% and ranged from 4.4-10.8% (n=24). 
 
2.5 Genotyping 
 
All genotyping were performed according to the quality handbook of the Department of 
Psychopharmacology. Venous blood samples were collected in vials containing 
ethylenediaminetetraacetic acid (EDTA) to prevent clotting. Leukocyte-DNA was isolated by 
solid phase extraction.  
 
2.5.1 Extraction of leukocyte DNA 
 
DNA was extracted with a “QIAmp - DNA Blood Mini Kit”: 
-Protease, 200µl whole blood and a buffer were mixed to lyse blood cells and break down 
proteins (e.g. enzymes and histones).  
-200µl ethanol was added to modify the solubility before application of DNA to the column. 
-The mixture was applied to the silica column and allowed to bind for 1 minute.  
-The column was washed two times with 500µl buffer. 
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-Eluation of the DNA was performed with 200µl AE-buffer. 
200µl whole blood yields 3-12µg DNA, consisting of fragments up to 50kb in size. Most of 
the DNA fragments will be approximately 20-30kb.  
2.5.2 Polymerase chain reaction (PCR) 
DNA from the extraction was mixed with the following: 
-heat stable DNA-polymerase  
-primer  
-all nucleoside triphosphates (A, C, G and T) 
-water, buffer and MgCl2 
A temperature program was run to produce a sufficient number of copies of the wanted DNA 
fragments. Different primers were used to produce the specific fragments. The PCR reactions 
were carried out on a Dyade Thermal Cycler (MJ Research, VWR international)  
 
General procedure for the PCR reaction:  
-Denaturation: The target DNA was heated to 95°C so that complementary strands separate.  
-Annealing: The temperature was lowered to 54-60°C (temperatures of annealing are variable 
among the methods and are only indicated by this interval). Primers with a sequence 
complementary to the strands were allowed to bind. Because primers were added in excess, 
the strands mostly annealed to the primer instead of each other. Primers are constructed to 
prevent primer-dimerization or production of secondary structures.  
-Extension: The temperature was increased to 72°C. The heat stable DNA polymerase 
extended the primers with nucleoside triphosphates and produced copies of the target 
sequence.  
This process was repeated 21-35 times (depending on method), to produce sufficient number 
of copies. 
2.5.3 Restriction cutting and electrophoresis of the target DNA 
 
Specific restriction enzymes were added to the DNA mixture and allowed to work for 2 hours.  
Restriction enzymes cut the DNA in specific areas. Electrophoresis was used to separate the 
DNA fragments by size. Samples were filled in wells on an agarose / polyacrylamide gel-plate 
covered with TAE buffer to allow migration of DNA. A positive and a negative electrode 
were inserted in the gel and 75 volts were applied for 60 minutes. This caused the fragments 
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to move through pores in the gel, negatively charged DNA- molecules move towards the 
positive pole. Ethylene bromide was added to the gel to bind to the DNA-fragments and 
absorb ultra violet (UV)-light. Detection was performed with an UV-camera. The fragments 
were separated according to mass and size, and were detected by use of positive controls and 
standard sized fragments. A DNA-free sample in each run was used to rule out contamination 
by foreign DNA. A homozygote sample will usually appear as one band, reflecting that all 
DNA is either cut or uncut by the restriction enzyme. Heterozygote samples will appear as 
two bands; reflecting half of the DNA cut and half of the DNA uncut. See fig 2-1. 
 
 
 
Fig 2-1: Electrophoresis of CYP2C9*2, from the left: Fragments with standard size 
(M100bp), heterozygote control (two bands), homozygote control (one band, approx 700 base 
pairs), normal control (one band, approx 500 base pairs), 3 patients, negative control 
(÷DNA) and fragments with standard size (M100bp). The wild type DNA was in this case cut 
by restriction enzymes and therefore consisted of smaller fragments that moved further 
through the gel. Wells are indicated by the squares at the top of the picture. 
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Table 2-1: Mutations in CYP isoenzyme 2C and 2D6 studied  
 
ISOENZYME MUT. Mechanism of mutation Result 
CYP 2C9 *2 Exon3, 430C→T, Arg144Cys Loss of effect 
CYP 2C9 *3 1075A→C, I359L Loss of effect 
CYP 2C9 *5 1080C→G, D360E Loss of effect 
CYP 2C19 *2 Exon5, 681G→A, splicing def. Defect enzyme 
CYP 2C19 *3 Exon4, 634G→A, stop codon. Defect enzyme 
CYP 2C19 *4 GTG initiation codon, 1A→G, No enzyme prod. 
CYP 2C19 *5 R433W, 1297C→T No enzyme prod. 
CYP 2D6 *2 X N (duplication →UM) Ultra rapid met. 
CYP 2D6 *3 2549A→DEL, frameshift Loss of effect 
CYP 2D6 *4 1846G→A, splicing defect Loss of effect 
CYP 2D6 *5 CYP2D6 gene deletion  (PM) Poor metabolizer 
CYP 2D6 *6 1707T→DEL, frameshift Loss of effect 
CYP 2D6 *7 2935A→C, H324P Loss of effect 
CYP 2D6 *8 1758G→T, stop codon. Loss of effect 
 
Mechanism of the different mutations and indication of their clinical implication are covered 
in table 2-1 (Bradford;Desta et al.;Lee et al.). 
 
Long PCR (multiplex-PCR) were used to detect CYP2D6 *3, *4, *6, *7, *8. A fragment that 
contained the complete CYP2D6 gene were amplified and detected by gel electrophoresis. 
This fragment was added allele specific primers for the five mutations, went through a new 
round of PCR and were detected by gel electrophoresis.  
 
CYP2C9*2, CYP2C9*3, CYP2C9*5 and CYP2C19 *2-*5 were amplified by use of allele 
specific primers, cutting with restriction enzymes and detection by gel-electrophoresis.   
 
CYP2D6*2 (duplication) and CYP2D6*5 (deletion) were amplified by use of allele specific 
primers and detection by gel-electrophoresis. These fragments are only amplified when the 
mutations are present.  
 
The analytical methods used in this project do not quantify the number of active copies in 
CYP2D6 gene duplication.   
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2.6 Entering data in SPSS 
 
All data were entered in SPSS 11.0 for Windows (SPSS Inc., Chicago, IL, USA)  
 
Table 2.2: Categories in SPSS. Following variables were entered in the database: 
 
Nr. Name Type (unit) Values 
(valid) 
Additional information 
1 Number Continuous, 
chronological 
1->   
2 Initials String -   
3 Institution Categorical 1->   
4 Duration of current drug regime Continuous, 
months 
1->   
5 Gender Categorical 1, 2 1=male 2=female 
6 Age Continuous, years     
7 Onset of psychiatric disease (age) Continuous, years 1->   
8 Duration of psychiatric disease  Continuous, years   
9 Height of the patient Continuous, 
centimetres 
1->   
10 Weight of the patient Continuous, 
kilograms 
1->   
11 Body mass index Continuous, (kg/m 
x m) 
    
12 Number of cigarettes smoked per 
day 
Continuous, 
cigarettes 
0->   
13 Antipsychotic medication ranked 
# 1  
Categorical, 
generic name 
1 to 15   
14 Daily dose of antipsychotic # 1 Continuous, 
milligrams 
    
15 CD-ratio of antipsychotic #1 
 
Continuous, 
((nmol/L)/(mg)) 
    
16 Serum concentration 
antipsychotic # 1 
Continuous, 
(nmol/L ) 
    
17 Antipsychotic medication ranked 
# 2  
Categorical, 
generic name 
1 to 15   
18 Daily dose of antipsychotic # 2 Continuous, 
milligrams 
    
19 CD-ratio for antipsychotic #2 Continuous, 
((nmol/L)/(mg)) 
    
20 Serum concentration 
antipsychotic # 2 
Continuous, 
(nmol/L) 
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21 Antipsychotic medication ranked 
# 3  
Categorical, 
generic name 
1 to 15   
22 Daily dose of antipsychotic # 3 Continuous, 
milligrams 
    
23 CD-ratio of antipsychotic #3 Continuous, 
(nmol/L/mg) 
    
24 Serum concentration 
antipsychotic # 3  
Continuous, 
(nmol/L) 
    
25 Use of any CYP2D6 substrate Categorical 1, 2  0=no, 1=yes 
26 Co medication 1  Categorical 1 to 8  
27 Co medication 2  Categorical 1 to 8  
28 Co medication 3  Categorical 1 to 8  
29 Total number of co medication drugs Continuous     
30 Use of a CYP450 inducer Categorical 0, 1 0=no, 1=yes 
31 Use of a CYP450 inhibitor Categorical 0, 1  0=no, 1=yes 
32 Diagnosis ICD-10 Categorical 201-390  
33 CYP2C9 *2 Categorical 1, 2, 3 1=normal, 2=hetero, 3=homo 
34 CYP2C9 *3 Categorical 1, 2, 3 1=normal, 2=hetero, 3=homo 
35 CYP2C9 *5 Categorical 1, 2, 3 1=normal, 2=hetero, 3=homo 
36 CYP2C19 *2 Categorical 1, 2, 3 1=normal, 2=hetero, 3=homo 
37 CYP2C19 *3 Categorical 1, 2, 3 1=normal, 2=hetero, 3=homo 
38 CYP2C19 *4 Categorical 1, 2, 3 1=normal, 2=hetero, 3=homo 
39 CYP2C19 *5 Categorical 1, 2, 3 1=normal, 2=hetero, 3=homo 
40 CYP2D6 *2 Categorical 1, 2, 3 1=normal, 2=hetero, 3=homo 
41 CYP2D6 *3 Categorical 1, 2, 3 1=normal, 2=hetero, 3=homo 
42 CYP2D6 *4 Categorical 1, 2, 3 1=normal, 2=hetero, 3=homo 
43 CYP2D6 *5 Categorical 1, 2, 3 1=normal, 2=hetero, 3=homo 
44 CYP2D6 *6 Categorical 1, 2, 3 1=normal, 2=hetero, 3=homo 
45 CYP2D6 *7 Categorical 1, 2, 3 1=normal, 2=hetero, 3=homo 
46 CYP2D6 *8 Categorical 1, 2, 3 1=normal, 2=hetero, 3=homo 
47 Group Categorical 1, 2 1= patient, 2=control 
48 Does patient smoke Categorical 0, 1  0=no, 1=yes 
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Table 2.3: (*) Rating of antipsychotic medication -This rating was  
done to simplify and guide the registration of antipsychotic medication in SPSS.  
 
Rating Generic name Trade name 
1 Clozapine Leponex® 
2 Olanzapine Zyprexa® 
3 Risperidone Risperdal® 
4 Quetiapine Seroquel® 
5 Ziprasidone Zeldox® 
6 Amisulpride Solian® 
7 Zuclopenthixol Cisordinol® 
8 Perphenazine Trilafon® 
9 Flupenthixole Fluanxol® 
10 Haloperidol Haldol® 
11 Thioridazine Melleril® 
12 Levomepromazine Nozinan® 
13 Chlorprothixene Truxal® 
14 Dixyracine Esucos® 
 
Table 2.4: Grouping of concomitant medication, denoted by ATC group (**) 
 
Nr  ATC  
1 N03 Antiepileptic 
2 N07 Antidepressive 
3 N05 B/C Anxiolytic/hypnotic/sedative 
4 N04 Anticholinergic 
5 N07 Other CNS 
6 C Cardiovascular drugs 
7 A GI, enzymes, antidiabetics 
8 Other ATC Other drugs 
 
2.7 Statistical tests and methods 
 
Parametric tests assume that the observations in each group are equally distributed and 
standard deviations are similar in the two groups. If this is not the situation a non-parametric 
method should be applied instead. To test differences in genotype between patient- and 
control group the chi-square test was used. Student t-test, a parametric method used to 
compare two independent groups of data was used when applicable. Statistical significance 
was considered a two-tailed p<0.05. Correlation is a connection between two continuous 
variables, and is defined by a coefficient ranging from –1 to 1. Pearson’s correlation 
coefficient was applied because data was evenly distributed (parametric test). Spearman 
correlation (non-parametric) was used solely to control the results. The Bonferoni test was not 
applied due to the explorative and descriptive nature of this project.  
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2.8 Ratios 
 
Concentration to dose ratio (CD-ratio) was obtained by dividing serum concentrations 
(nmol/L) with daily antipsychotic dose (mg). This parameter could indicate deviation in 
clearance or bioavailability. Relative CD ratio was obtained by dividing each patient’s CD 
ratio with the mean CD ratio of this antipsychotic. This was done to compare CD ratios for 
different antipsychotic substances. Some of the patients were treated with depot injections. 
Depot doses are multiplied with a bioequivalence (bioavailability) factor of 2, so that 
distribution routes can be compared. The method assumes a bioavailability of 50% per oral, 
and 100% with parenteral administration. This is a conventional method used in psychiatry; 
however this is not pharmacologically correct.   
2.9 Registration of concomitant medication 
 
In the registration of concomitant medication, only three different substances were coded. All 
concomitant medication was investigated to discover potential drug to drug interactions. In 
addition to this information, the total number of concomitant drugs was recorded.  
 
2.10 Therapeutic range, standard dosing and defined daily 
doses (DDD) 
 
Therapeutic reference ranges were obtained from the literature, or from TDM of 
antipsychotics, but also from PK studies. Standard dosing was obtained from product résumés 
and PK studies. DDD were obtained from the WHO Collaborating Centre for Drug Statistics, 
which publish DDD for all available ATC numbers. (WHO)  (Baumann et al.).  
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3 RESULTS  
3.1 Patient age, onset and duration of illness 
 
109 patients (73 men and 36 women) out of totally 112 screened met the inclusion criteria of 
the study. The patient age ranged from 28 to 86 years with a mean age of 55 years (SD 11 
years). The onset of the psychiatric disease ranged from 9 to 60 years with a mean age of 24 
years. The duration of the disease ranged from 3 to 60 years, mean 31 years (SD 13). The 
duration of the patient’s current drug regime ranged from 1 to 372 months with an average of 
25 months (SD 42 months). Information about changes in drug regime was obtained from 
patient records. It states the time from last change of dose or substance in the patient’s 
antipsychotic drug regime.  
3.2 Diagnoses  
 
90 out of 109 patients in this study were diagnosed with schizophrenia (F20.0-F20.9). The 
most frequent diagnoses were paranoid- (61 patients) or hebephrenic schizophrenia (24 
patients). 5 patients were diagnosed with other types of schizophrenia, 7 patients were 
schizoaffective and 5 patients were bipolar. See also table 3-1. The rest of the patients had 
different diagnoses characterized with schizophrenic or psychotic symptoms.  
 
Table 3-1: Diagnoses according to ICD 10  
 
Number of patients ICD10 Code Diagnosis 
61 F20.0 Paranoid schizophrenia 
24 F20.1 Hebephrenic schizophrenia 
1 F20.2 Catatonic schizophrenia 
1 F20.3 Undifferentiated schizophrenia 
1 F20.5 Residual schizophrenia 
2 F20.9 Unspecified schizophrenia 
7 F22.0 Paranoid psychosis 
4 F25.0 Schizoaffective, manic type 
3 F25.2 Schizoaffective, mixed type 
5 F31.6 Bipolar affective 
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3.3 Pharmacotherapy of the patient group 
 
The patient group received treatment with an average of 1.5 different antipsychotics (54 
patients received one, 43 patients two and 12 patients received three different antipsychotics). 
See table 3-3. The patients used an average of 2.2 DDD (SD 1.5) of antipsychotic medication.  
Primary antipsychotics were dosed an average of 1.6 DDD (SD 0.8) in our patient group. 
Secondary antipsychotics were dosed an average of 1.0 DDD (SD 1.3) and tertiary 
antipsychotics were dosed an average of 0.3 DDD (SD 0.2).  
 
Blood serum levels were tested for 171 antipsychotics. The most commonly used drug was 
olanzapine (43 patients), clozapine (33 patients), levomepromazine (23 patients), risperidone 
(16 patients), perfenazine (15 patients), zuclopenthixol (15 patients) and haloperidol (10 
patients). See table 3-3. 
 
Table 3-2: Patients treated with different antipsychotics as primary, secondary and tertiary 
substance. 
 
Primary 
antipsychotic 
n Secondary 
antipsychotics 
n Tertiary 
antipsychotics 
N 
Clozapine 32 olanzapine 1 perfenazine 1 
Olanzapine 42 risperidone 4 levomepromazine 9 
Risperidone 12 quetiapine 2   
Quetiapine 2 ziprasidone 1   
zuclopenthixol 6 amisulprid 2   
perphenazine 5 zuclopenthixol 9   
flupenthixole 2 perfenazine 9   
Haloperidol 4 flupenthixole 2   
thioridazine 2 haloperidol 6   
  thioridazine 1   
  levomepromazine 14   
  chlorprotixene 3   
  dixyrazine 1   
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Table 3-3: Generic and brand name of antipsychotics, number of patient per substance, DDD 
(defined by WHO) and CYP-isoenzyme involved (WHO), (Dahl). 
 
Substance Trade name  n-patients DDD CYP-ENZYME 
Olanzapine Zyprexa ® 43 10mg CYP1A2 
Clozapine Leponex ® 33 300mg CYP1A2 
Levomepromazine Nozinan ® 23 300mg CYP2D6 
Risperidone Risperdal ® 16 5mg CYP2D6 
Perfenazine Trilafon ® 15 30mg CYP2D6 
Zuklopenthixol Cisordinol ® 15 300mg CYP2D6 
Haloperidol Haldol ® 10 8mg CYP2D6 
Quetiapine Seroquel ® 4 400mg CYP3A4 
Flupenthixole Fluanxol ® 4 6mg CYP2D6 
Chlorprotixene Truxal ® 3 30mg CYP2D6 
Thioridazine Melleril ® 3 300mg CYP2D6 
Dixyrazine Esucos ® 1 50mg NA 
Ziprazidone Zeldox ® 1 80mg NA (Renal) 
 
 
3.4 Serum concentrations and dosing of antipsychotics 
Data were only included in this section for antipsychotics used by more than 10 patients. For 
additional information, see table 3-5. Quite a few patients had serum concentrations below or 
above reference range, 18% and 25% respectively. Most of the cases of serum concentrations 
below reference range (n=30) are caused by levomepromazine (n=22), the rest of the cases 
involve haloperidol (n=4); perphenazine (n=2); quetiapine (n=1) and risperidone (n=1). See 
table 3-4. 
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Table 3-4: The number of patients that showed serum concentrations below, within or above 
the reference range 
 
Ref. range ANTIPSYCHOTIC#1 ANTIPSYCHOTIC#2 ANTIPSYCHOTIC#3 N % 
BELOW 3 19 8 30 18% 
NORMAL 70 22 1 93 57% 
ABOVE 30 10 1 41 25% 
TOTAL 105 50 11 164  
 
3.4.1 Olanzapine 
43 patients received treatment with olanzapine and valid serum concentrations were collected 
from 42 of these patients. The average serum concentration was 157 nmol/L (SD 133), while 
the reference range are 30-200 nmol/L. The doses ranged from 5-50 mg daily, with an average 
of 20 mg (SD 9). Recommended daily dose is 10-25 mg daily. Olanzapine were used as 
monotherapy in 16 patients, together with typical antipsychotics in 23 patients and in 
combination with atypical antipsychotics in 4 patients. Dose-response relationship shows high 
intra individual differences of a given dose. 
3.4.2  Clozapine 
33 patients received treatment with clozapine. The average serum concentration was 1508 
nmol/L (SD 742), while the reference range are 200-2000 nmol/L. Average daily dosing was 
480 mg (SD 157), while recommended dosing of clozapine range from 50-900 mg. Clozapine 
were used as monotherapy in 19 patients, in combination with typical antipsychotics in 8 
patients and in combination with atypical antipsychotics in 6 patients.  A dose-response 
relationship shows high intra individual differences of a given dose.  
3.4.3 Risperidone  
16 patients received treatment with risperidone. The average serum concentration was 106 
nmol/L (SD 62), while the reference range are 30-120 nmol/L.  Average daily dosing was 5 
mg (SD 3), while the recommended dosing range from 2-12 mg. Risperidone were used as 
monotherapy in 7 patients, in combination with a typical antipsychotics in 5 patients and in 
combination with a typical antipsychotics in 4 patients.  
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3.4.4 Perphenazine  
15 patients received treatment with perphenazine. The average serum concentration was 11 
nmol/L (SD 16), while the reference range are 2-6 nmol/L. Average daily dosing was 22 mg 
(SD 20), while recommended dosing range from 8-64 mg. Perphenazine were used as 
monotherapy in 2 patients, in combination with typical antipsychotics in 3 patients and 
together with atypical antipsychotics in 10 patients.     
3.4.5 Haloperidol 
10 patients received treatment with haloperidol. The average concentration was 12 nmol/L 
(SD 9), while the reference range are 7-30 nmol/L. Average daily dosing was 10 mg (SD 12), 
while recommended dosing range from 2-20 mg. Haloperidol were used in monotherapy in 3 
patients, together with a typical antipsychotics in 1 patient and in combination with atypical 
antipsychotics in 6 patients. Four patients showed serum concentrations below reference 
range. 
3.4.6 Zuclopenthixol 
15 patients received treatment with zuclopenthixol. The average serum concentration was 43 
nmol/L (SD 41), while the reference range are 7-30 nmol/L. Average daily dosing was 37 mg 
(SD 33), while recommended dosing range from 10-60 mg. Zuclopenthixol were used in 
monotherapy in 4 patients, together with typical antipsychotics in 2 patients and in 
combination with atypical antipsychotics in 9 patients. 
3.4.7 Levomepromazine 
23 patients received treatment with levomepromazine. The average concentration was 79 
nmol/L (SD 55), while the reference range are 150-800 nmol/L. Average daily dosing was 64 
mg (SD 104), while recommended dosing range from 10-600 mg. Levomepromazine were not 
used in monotherapy, in combination with typical antipsychotics in 4 patients and in 
combination with atypical antipsychotics in 19 patients. 22 out of 23 patients treated with 
levomepromazine showed serum concentrations below reference range.  
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Table 3-5: Results from patient group; data are only included for antipsychotics used in more 
than five patients. Average values and standard deviations are included for BMI, number of 
daily cigarettes, age of onset psychiatric disease, serum concentrations, daily dosing and 
concentration to dose (CD) ratio. Reference values for serum concentrations and daily dosing 
are obtained from literature.    
 
 
 
 
 
Generic name 
Serum 
concentr. 
(nmol/L) 
Reference 
range 
(nmol/L) 
Average dosing 
(mg) 
Reference 
dosing 
 
Average 
CD-ratio 
Clozapine 1508 SD 742 200-2000 483 mg SD 157 50-900mg 3.4 
Olanzapine 158 SD 132 30-200 20.4 mg SD 8.6 10-25mg 8.1 
Risperidone 106 SD 62 30-120 5.0 mg SD 2.7 2-12 21.4 
Quetiapine 206 SD 140 100-800 775 mg SD 206 150-750mg - 
Ziprasidon (511) 30-200 (160 mg) 40-160mg - 
Amisulpride (3380) 400-1500 (800 mg) 100-900mg - 
Zuclopenthixol 43.2 SD 40.5 7-30 37.0 mg SD 32.5 10-60mg 1.3 
Perphenazin 10.6 SD 16.3 2-6 21.8 mg SD 19.8 8-64 mg 0.4 
Flupenthixol 13.1 SD 8.0 2-8 23.0 mg SD11.5 2-12 mg - 
Haloperidol 11.8 SD 9.2 7-30 10.2 mg SD 11.8 2-20 mg 2.0 
Thioridazine - - - - - 
Levomepromazin 78.6 SD 55 150-800 64 mg SD 104.5 10-600mg 0.8 
Chlorprotixene - 100-800 - 100-200mg - 
Dixyracine - - - - - 
 
 
 
 
 
 
 
Generic name 
Brand 
name Patients BMI n cigarettes 
Age of 
onset 
clozapine Leponex® 33 27.6 SD 4.2 15.5 SD 9.7 22.3 SD 6 
olanzapine Zyprexa® 43 26.7 SD 5.3 13.8 SD 10.7 23.5 SD 8.2
risperidone Risperdal® 16 25.2 SD 4.6 13 SD10.8 22.8 SD 8.7
quetiapine Seroquel® 4 27.0 SD 3.0 7.0 SD 8.7 20.7 SD 2.9
ziprasidone Zeldox® 1 (27.5) (12) (27) 
Amisulprid Solian® 2 (27.4) (10) (22) 
zuclopenthixol Cisordinol® 15 24.5 SD 2.9 12 SD 10.6 22 SD 6.6 
perphenazine Trilafon® 15 27.0 SD 4.0 17 SD 16.0 22.4 SD 5.6
flupenthixole Fluanxol® 4 24.9 SD 5.0 17 SD17.4 31 SD 19.5 
Haloperidol Haldol® 10 27.6 SD 5.5 14.7 SD10.6 22.6 SD11.5
thioridazine Melleril® 3 - - - 
levomepromazin Nozinan® 23 25.7 SD 4.7 17 SD 10 21.3 SD 6.6
chlorprotixene Truxal® 3 - - - 
dixyracine Esucos® 1 - - - 
    176    
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3.5 Smoking habits 
 
Eighty-two out of 109 patients (75%) smoked cigarettes, while 27 patients (25%) were non-
smokers. The average number of daily cigarettes among smokers was 18 (SD 9). The number 
of cigarettes per day ranged from 2 to 50. According to a survey from 2002, 28% of the 
Norwegian population aged 18 or older smoked tobacco (Statistics Norway). Smoking habits 
are displayed in fig. 3-1. 
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Fig 3-1: Number of daily cigarettes 
3.5.1 Weight and BMI 
 
Height and weight were collected from 105 out of 109 patients. BMI values ranged from 18.4 
to 41.1. Average BMI was 27 (SD 5). Women had an average BMI of 29 and men a BMI of 
26. Fifty-five percent of the patients had BMI values within the normal range, while 17% 
were considered overweight and 26% were considered obese. In the general Norwegian 
population aged 45-66 years 10% are considered obese. (Statistics Norway) Weight gain is 
one of the most important side effects of treatment with atypical antipsychotics. The average 
BMI of the patients that received atypical antipsychotics was not different from the patients 
treated with typical antipsychotics (26.8 SD=4.8 and 27.0 SD=5). Among atypical 
antipsychotics, only three drugs were used in more than five patients and therefore included in 
this section.  
There were no significant differences in BMI between these three drugs, but risperidone 
patients seem to have lower BMI values. Average BMI for clozapine patients was 27.6 
(SD=4.2), olanzapine 26.7 (SD=5.3) and risperidone 25.2 (SD=4.6). See fig 3-2. 
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Fig 3-2: Confidence interval (95%): BMI values of patients treated with different atypical 
antipsychotics 
 
3.5.2 Concomitant medication 
 
Only three concomitant drugs were recorded for each patient, in addition the total number of 
concomitant drugs was recorded. Ninety-one out of 109 patients (83%) received at least one 
concomitant drug, other than antipsychotics. The average number of concomitant drugs was 
2.7 (SD 2.2). One patient received 10 drugs in addition to two different antipsychotics. 
Anatomic therapeutic chemical (ATC) class N was the most frequently prescribed. 
-ATC class N includes all central nervous system (CNS) drugs:  
-ATC N03: antiepileptics were prescribed to 58 patients.  
-ATC N06: psychoanaleptics were prescribed to 40 patients.  
-ATCN05: hypnotics/anxiolytics/sedatives were prescribed to 39 patients.  
 
-ATC class C, cardiovascular drugs, were prescribed to 21 patients.   
 -ATC C10 Serum lipid lowering agents were prescribed to 5 patients 
-ATC group A (e.g. GI-tractus and diabetes, endocrinology) was prescribed to 16 patients. 
-Other ATC groups were represented in 25 patients.  
For additional information see table 3-6. 
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Table 3-6: Concomitant medication, classified after ATC groups.  
 
ATC group: Comed. # 1 Comed. # 2 Comed. # 3  Sum 
N03 Antiepileptics 49 8 1 58 
N06 Psychoanaleptics 14 21 5 40 
N05 B/C Hypn./anxiol./sedatives 9 13 17 39 
N04 Antiparkinson anticholinergics 7 5 4 16 
C Cardiovascular drugs 4 12 5 21 
A GI-tractus, diabetes, endocrinology 3 7 6 16 
Other ATC 5 7 13 25 
Sum 91 73 51 215 
3.6 Impact of CYP2D6 genotype on serum concentrations 
 
3.6.1 Ultra rapid metabolizers - CYP2D6 *2 Gene duplication  
 
Four patients were positive for CYP2D6 gene duplication and are briefly discussed in 
this section: 
 
Patient 1:  
60-year-old male treated with 18 mg zuclopenthixol (0.6 DDD) in combination with 
olanzapine. Serum concentration of zuclopenthixol was 19 nmol/L, while the reference range 
is 7-30 nmol/L. The patient has no other CYP-mutations and did not receive CYP inducers or 
inhibitors. However the impact of gene duplication appears to be minor in this patient.  
 
Patient 2:  
60-year-old female, treated with 50 mg chlorprothixene (1.7 DDD) in combination with 
clozapine. Serum concentration of chlorprothixene was 20 nmol/L, while the reference range 
is 100-800 nmol/L. The patient has no other CYP-mutations and did not receive CYP-
inducers or inhibitors. A serum concentration far below the therapeutic range and normal 
dosing indicates a high CYP2D6 clearance in this patient. The patient received this treatment 
the last 5 years prior to testing.   
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Patient 3:  
57-year-old male, treated with 4 mg haloperidol (0.5 DDD) in combination with olanzapine. 
Serum concentration of haloperidol was 15 nmol/L, while the therapeutic range is 7-30 
nmol/L. The patient has no other CYP-mutations and did not receive CYP inducers or 
inhibitors. Impact of gene duplication appears to be minor in this patient.  
 
Patient 4:  
60-year-old female treated with olanzapine and amisulpride, none of these antipsychotics are 
mainly metabolized by CYP2D6.  
 
3.6.2 CYP2D6 poor metabolizers  
Five poor metabolizers were found in the group: Two CYP2D6 *4 / *5 compound poor 
metabolizers and three CYP2D6 *4 / *4 poor metabolizers:    
Patient 1: 
70-year-old female treated with risperidone 5 mg (1 DDD). The serum concentration was 261 
nmol/L, while the reference range is 30-120 nmol/L. Average serum concentration for the 15 
other patients in the group was 106 nmol/L (SD 62), denoting that this patient has a serum 
concentration 2.4 times the standard deviations and a relative exposure of 2.5 times higher 
than the rest of the group. CD ratio for this patient was 58, while the mean CD ratio of the 
group was 21.4. Relative CD ratio for risperidone was 2.7. 
 
Patient 2:  
49-year-old male treated with risperidone 1 mg (0.2 DDD) in combination with clozapine. 
Serum concentration of risperidone was 51 nmol/L, while the therapeutic range is 30-120 
nmol/L. The CD ratio of risperidone was 51 and the average CD ratio was 21.4 in the group.  
A high CD ratio in this patient denotes a low CYP2D6 clearance. The patient did not receive 
CYP inhibitors or inducers and dosing appears to be well titrated in this patient. Relative CD 
ratio for risperidone was 2.4. 
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Patient 3: 
67-year-old male treated with flupenthixole 20 mg (3.3 DDD) and levomepromazine 25 mg 
(0.08 DDD) in combination with olanzapine. Serum concentrations were 34 nmol/L for 
flupenthixole (reference range: 2-8 nmol/L) and 23 nmol/L for levomepromazine (reference 
range: 10-600 nmol/L). No CD ratio was obtained for flupenthixole (N=4), but the CD ratio 
for levomepromazine was 0.92 with an average in the group of 0.83. Relative CD ratio for 
levomepromazine was 1.1. 
 
Patient 4:  
62-year-old male treated with zuclopenthixol 49 mg (1.7 DDD). The serum concentration was 
45 nmol/L, while the therapeutic range is 7-30 nmol/L. The CD ratio was 0.92, with an 
average in the group of 0.32. Relative CD ratio for zuclopenthixol was 0.7. 
 
Patient 5: Was not treated with CYP2D6 substrate.  
3.6.3 Intermediate metabolizers 
 
CYP2D6 *1 / *3 
Only one patient was heterozygote positive CYP2D6 *3. This patient was not treated with 
CYP2D6 substrates. 
 
CYP2D6 *1 / *4 
20 of the 30 patients with a heterozygote CYP2D6*4 mutation received treatment with a 
CYP2D6 substrate.  Relative CD ratio for the CYP2D6 substrates was 1.28 (SD=1.04). The 
CD-ratio denoted slightly decreased clearance but the standard deviation indicates a high 
degree of variation.  
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CYP2D6 *1 / *5 
5 patients were positive for the CYP2D6 *1 / *5 mutation (deletion of the enzyme). Four of 
these patients were treated with CYP2D6 substrates and are briefly described in this section:  
 
Patient 1:  
54-year-old male treated with risperidone 5 mg (1 DDD). The serum concentration was 158 
nmol/L, while the reference range is 30-120 nmol/L. The CD ratio of this patient was 31.6, 
the average in the risperidone group was 21.44. This indicates decreased risperidone clearance 
in this patient. Relative CD ratio: 1.47. 
 
Patient 2:  
55-year-old male treated with and zuclopenthixol 50 mg (1.7 DDD), in combination with 
olanzapine. Serum concentration of zuclopenthixol was 43 nmol/L, while the reference range 
is 7-30 nmol/L. The CD ratio was 0.86, while average in the zuclopenthixol group was 1.32. 
Zuclopenthixol clearance in this patient is higher than average, indicating no clinical 
relevance of CYP2D6 gene deletion. Relative CD ratio: 0.65.  
 
Patient 3: 
57-year-old female treated with levomepromazine 50 mg (0,17DDD) in combination with 
olanzapine 15 mg. Serum concentration of levomepromazine was 61 nmol/L, while the 
reference range is 150-800 nmol/L. The CD ratio of this patient was 1.22 compared to 0.83 
for the rest of the group. A higher CD ratio than average indicates decreased clearance for 
levomepromazine. Relative CD ratio: 1.47. 
 
Patient 4:  
40-year-old female treated with olanzapine 35 mg and perfenazine 5 mg (0.17DDD). Serum 
concentration of perfenazine was 3.1 nmol/L (Ref: 2-6 nmol/L). The CD ratio of this patient 
was 0.60 compared to 0.39 for the rest of the group. Perfenazine clearance was higher than 
average for the group. Relative CD ratio: 1.54. 
   
CYP2D6 *1 / *6 
Two patients were positive for a heterozygote CYP2D6 *6, but none of them were treated 
with antipsychotics metabolized by CYP2D6.   
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3.7 Genotype of patients compared with control group 
 
The patient group (n=109) consisted of 73 men and 36 women with a mean age of 55 years. 
The control group (n=136) consisted of 51 men and 85 women with a mean age of 32 years. 
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Fig 3-3: Allele frequencies CYP2D6: patients, controls and Caucasian groups (literature) 
 
 
 
 
Fig 3-4: Allele frequencies CYP2C9: patients, controls and Caucasian groups (literature) 
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Fig 3-5: Allele frequencies CYP2C19: patients, controls and Caucasian groups (literature) 
 
Table 3-7: Allele frequencies for patient group, control group and Caucasian literature 
values.  
 
CYP2C9 PATIENT CONTROL LITERATURE REF 
*2 15.1 14 11.3 1 
*3 6.4 8.1 6.7 1 
*5 0 0 - - 
     
CYP2C19 PATIENT CONTROL LITERATURE  
*2 14.2 15.4 19.2 2 
*3 0 0 - - 
*4 0 0.4 - - 
*5 0 0 - - 
     
CYP2D6 PATIENT CONTROL LITERATURE  
*2 1.83 0.7   
*3 0.45 0.4 1.6 3 
*4 15.1 19.9 19.4 3 
*5 3.2 3.3 4.1 3 
*6 0.9 0.4 1 3 
*7 0 0 - - 
*8 0 0 - - 
     
1. Lee CR, et al. Pharmacogenetics 2002; 12: 251-63. (CYP2C9) 
2. Desta Z, et al. Clin Pharmacokinet 2002; 41: 913-58. (CYP2C19) 
3. Bradford LD. Pharmacogenomics 2002; 3: 229-43. (CYP2D6) 
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Table 3-8: CYP2D6 genotype in patient group (n=109), control group (n=136) and total 
number for all genotyped subjects (n=245). No subjects were positive for CYP2D6 *7 or 
CYP2D6 *8 genotype and are therefore not included 
 
 PATIENT CONTROL TOTAL 
Genotype  N Fraction N Fraction N Fraction 
Poor metabolizers:       
CYP2D6 *4 / *4 3 2.8% 3 2.2% 6 2.4% 
CYP2D6 *4 / *5 2 1.8% 1 0.7% 3 1.2% 
Total PM CYP2D6 5 4.6% 4 2.9% 9 3.6% 
Intermediate metabolizers:       
CYP2D6 *1 / *3 1 0.9% 1 0.7% 2 0.8% 
CYP2D6 *1 / *4 25 22.9% 47 34.6% 72 29.4% 
CYP2D6 *1 / *5 5 4.6% 8 5.9% 13 5.3% 
CYP2D6 *1 / *6 2 1.8% 1 0.7% 3 1.2% 
Total IM CYP2D6 33 30.3% 57 42.0% 90 36.7% 
Ultra rapid metabolizers:        
CYP2D6 *2  4 3.7% 2 1.5% 6 2.4% 
Extensive metabolizers:       
CYP2D6 *1 / *1 67 61.4% 73 53.7 140 57.1% 
Total 109 100% 136 100% 245 100% 
 
 
Table 3-9: CYP2C19 genotype in patient group (n=109), control group (n=136) and total 
number for all genotyped subjects (n=245). No subjects were positive for CYP2C19 *3 or 
CYP2C19 *5 genotype and are therefore not included. 
 
 PATIENT CONTROL TOTAL 
Genotype N Fraction N Fraction N Fraction 
Poor metabolizers:       
CYP2C19 *2 / *2 2 1.8% 1 0.7% 3 1.2% 
Intermediate metabolizers:       
CYP2C19 *1 / *2 27 24.8% 40 29.4% 67 27.4% 
CYP2C19 *1 / *4 0 0% 1 0.7% 1 0.4% 
Extensive metabolizers:       
CYP2C19 *1 / *1  80 73.4% 94 69.1% 174 71% 
Total 109 100% 136 100% 245 100% 
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Table 3-10: CYP2C9 genotype in patient group (n=109), control group (n=136) and total 
number for all genotyped subjects (n=245). No subjects were positive for CYP2C9 *5 
genotype and are therefore not included. 
 
 PATIENT CONTROL TOTAL 
Genotype N Fraction N Fraction N Fraction 
CYP2C9 *2 / *2 0 0% 5 3.5% 5 2.0% 
CYP2C9 *3 / *3 0 0% 1 0.7% 1 0.4% 
CYP2C9 *1 / *2  33 30.3% 28 20.6% 61 24.9% 
CYP2C9 *1 / *3  14 12.8% 20 14.7% 174 71% 
Total 109 100% 136 100% 245 100% 
 
 
Table 3-11: Allele frequencies in patient- and control group compared with the chi-square 
test. Allele frequencies = (number of mutations) / (number of subjects * 2). Because of the 
diploid human genome every person may have two mutations.   Heterozygote genotype counts 
as one and homozygote mutations counts as two mutations.    
 
Mutation Allele 
frequency 
patients 
Allele 
frequency 
controls 
Fishers exact test 
Sigma 2-sided 
Significant 
(p=0,5) 
CYP2C9 *2 15.1% 14% 0.67 NS 
CYP2C9 *3 6.4% 8.1% 0.59 NS 
CYP2C9 *5 - - - - 
CYP2C19 *2 14.2% 15.4% 0.78 NS 
CYP2C19 *3 - - - - 
CYP2C19 *4 0% 0.4% - - 
CYP2C19 *5 - - - - 
CYP2D6 *2 1.83% 0.7% 0.41 NS 
CYP2D6 *3 0.45% 0.4% - - 
CYP2D6 *4 15.1% 19.9% 0.14 NS 
CYP2D6 *5 3.2% 3.3% - - 
CYP2D6 *6 0.9% 0.4% 0.59 NS 
CYP2D6 *7 - - - - 
CYP2D6 *8 - - - - 
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3.8 Impact of environmental factors on the serum 
concentrations of antipsychotics 
 
3.8.1 Use and impact of CYP inducers 
 
Five out of 109 patients (4.6%) received treatment with CYP inducers. All five patients used 
carbamazepine in doses ranging from 400-1300 mg daily (mean 780 mg daily).  
Two of these patients received only CYP2D6 substrates, not relevant here because this 
enzyme is not prone to induction. One patient received only a CYP3A4 substrate and the two 
last patients receive both a CYP1A2 and CYP2D6 substrate. The three patients treated with 
CYP1A2 and CYP3A4 substrates are briefly described in this section:  
 
Patient 1: 
60-year-old male, treated with quetiapine 600 mg (1.5 DDD) and carbamazepine 600 mg. 
Serum concentration of quetiapine was 31 nmol/L, while the reference range is 100-800 
nmol/L. Subtherapeutic serum concentration indicates poor response of current quetiapine 
treatment. Mean CD ratio for the quetiapine group was 0.28, but this value was based on only 
four patients. The CD ratio of this patient was 0.05, indicating more than a fivefold increase in 
clearance compared with average quetiapine group 
 
Patient 2: 
50-year-old male, treated with haloperidol, levomepromazine, olanzapine 20 mg (2 DDD) and 
carbamazepine 400 mg. Serum concentration of olanzapine was 87 nmol/L, while the 
reference range is 30-200 nmol/L. The CD ratio for olanzapine was 4.35 while the mean CD 
ratio for the group was 8.1. A low CD ratio indicates high clearance. The patient smokes 20 
cigarettes per day.  
 
Patient 3: 
48-year-old male, treated with olanzapine 35 mg (3.5 DDD) and carbamazepine 1300 mg. 
Serum concentration of olanzapine was 142 nmol/L, while the reference range is 30-200 
nmol/L. The CD ratio was 4.06 while mean in the group was 8.1.  The patient does not smoke, 
and the inducer effect was probably related to carbamazepine.  
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3.8.2 Use and impact of CYP inhibitors  
No concomitant use of relevant inhibitors for isoenzyme CYP1A2, CYP2C9, CYP2C19 or 
CYP3A4 was registered in the patient group. Inhibitors of these enzymes include: antifungal 
agents, antibiotics, calcium-channel blockers, and antiviral agents. Several antidepressive 
agents (e.g. selective serotonin reuptake inhibitors (SSRI) fluvoxamine, fluoxetine and 
paroxetine) are characterized as potent inhibitors of CYP 2D6. Some of the patients used 
antidepressants, but none of the substances used were CYP inhibitors.  
 
30 out of 109 patients (27.5%) used a CYP inhibitor. Levomepromazine, perphenazine and 
bupropione are the only CYP inhibitors used in this group. Twenty-one of these patients used 
both a CYP 2D6 substrate and a CYP inhibitor. None of the patients used an SSRI described 
as an inhibitor. One patient used bupropione (Zyban®) for smoking cessation, bupropione 
being a potent inhibitor of CYP2D6. 
 
Twelve of the patients received a CYP inhibitor in combination with risperidone, 
zuclopenthixol or haloperidol. Average relative CD ratio in these 12 patients was 0.93 (SD 
0.39), indicating normal clearance. This does not support that levomepromazine, 
perphenazine and bupropione are considered potent CYP-inhibitors. The inhibitors were 
dosed an average of 0.4 DDD, this might explain the lack of influence on clearance. Some of 
the patients showed high ratios, but this was also associated with intermediate metabolizer 
genotype. The number of patients was too low to conclude if there are differences in the 
potency of the different inhibitors.  
 
3.8.3 Impact of smoking on antipsychotics metabolized by CYP1A2 
 
The CD ratio in the clozapine group (p=0.001), and in the olanzapine group (p=0.001), and 
the relative CD ratio for all CYP1A2 users (p<0.001) were significantly lower in smokers 
compared to non-smokers. The non-smokers in the clozapine group had 2.1 times higher CD 
ratios compared with smokers. The non-smokers in the olanzapine group had 1.9 times higher 
CD ratios compared to smokers. See also fig 3-6, 3-7, 3-8 and 3-9. 
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Fig 3-6: 95% CI for CD ratios in olanzapine smokers and non-smokers  
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Fig 3-7: 95% CI for CD-ratios in all CYP1A2 users (olanzapine/clozapine),  
denoted as SD from average value 
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Fig 3-8: Dosing and serum concentrations in smokers and non-smokers treated with 
clozapine 
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Fig 3-9: Dosing and serum concentrations in smokers and non-smokers treated with 
olanzapine 
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4 DISCUSSION 
4.1 Patient group 
 
This study describes a group of patients with long-term mental illness (31 years on an 
average) that has not responded well to treatment. In contrast most of the published studies in 
this field have focused on short time hospitalized patients or outpatients with a shorter 
psychiatric history. Age of disease onset in this study was 24 years, reflecting literature values 
for age of onset 16-30 years (Mueser and McGurk).  
 
The everyday lives of these patients are characterized by established routines for taking 
medication, meals, activities and sleep. Non-compliance or use of alcohol and illegal drugs 
was relatively rare in this population according to the patient records. Both non-compliance 
and illegal use of drugs is considered a major problem in younger patients and in outpatients 
in general. No study has, to our knowledge, described the pharmacological treatment of a 
group of schizophrenic patients living in nursing homes.  
4.1.1 Pharmacotherapy of schizophrenia in nursing homes  
 
Eighty percent of the patients were treated with at least one atypical antipsychotic, with 
olanzapine and clozapine as the far most abundant (70% of the patients). The most recent 
marketed antipsychotics quetiapine, amisulpride and ziprasidone were only used in treatment 
of 7 patients. This may reflect a threshold for trying new substances in patients with already 
established long-term treatment.  
 
Twenty percent of the patients received treatment with typical antipsychotics only. The low 
potency typical antipsychotics were dosed low according to WHO-defined DDD. This may be 
explained by utilization of the sedative effects of these antipsychotics primarily. It appears 
that WHO-defined DDD does not comply with current Norwegian clinical practice. Low 
potency typical antipsychotics are not being used as primary treatment of psychosis; rather in 
low doses to relieve agitation and restlessness associated with psychiatric disorders. 
Anxiolytic and sedative effects are pronounced in dosage far below the defined DDD. Clinical 
guidelines recommend the use of atypical antipsychotics as first line treatment of psychosis 
(Tanum). 
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4.1.2 Polypharmacy 
 
The average patient received 1.5 different antipsychotic substances, with a total dose 
corresponding with 2.2 DDD. A Norwegian study on consumption of antipsychotics showed 
an average use of 1.22 DDD/day in psychiatric hospitals in year 2000 (Rytter and Haberg). If 
our patient group is more severely ill than an average group of psychiatric hospital patients 
they might need higher doses of antipsychotics. Regulation of CNS receptors might require 
increased dosage in long-term treatment. The high daily dose may perhaps also indicate that 
current guidelines and trends are not complied.  
The Norwegian consumption study showed a total decrease in DDD of antipsychotic drugs 
during the 1990s. The use of typical antipsychotics decreased, while the use of atypical 
antipsychotics increased with 46% from 1991 to 2000. This trend might be explained by 
decreased use and dosage of the low potency typical antipsychotics. Increased use of atypical 
antipsychotics can be explained by marketing of several new substances, good tolerability and 
clinical experience that might lead to use of higher doses.  
4.1.3 Concomitant medication 
 
Psychotropic drugs 
Each patient received an average of 2.7 different concomitant drugs. Psychotropic drugs, 
excluding antipsychotics (ATC group N) constituted 70% of the concomitant medication. 
This profile might be explained by a shift from utilization of the sedative effect of low 
potency typical antipsychotics to increased use of mood stabilizers and benzodiazepines 
(Tanum). 
Antidepressive treatment was given to 40 patients. None of these patients were treated with 
the potent CYP2D6 inhibitors paroxetine, fluoxetine and fluvoxamine. Increased focus on 
drug interactions associated with some selective serotonin reuptake inhibitors (SSRI) might 
have influenced the choice of substance. 
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Somatic disorders and increased mortality in schizophrenic patients 
Mortality in schizophrenic patients is 2-3 times higher than in the general population. Most of 
this is related to somatic conditions (60-70%), with increased risk of cardiovascular diseases 
as the main reason. Side effects of atypical antipsychotics include metabolic complications 
like weight gain, hyperlipidemia and a higher incidence of diabetes mellitus. These side 
effects are more pronounced in patients treated with clozapine and olanzapine (Brown, Inskip 
and Barraclough). Low activity level and heavy smoking are factors that suggest close 
monitoring of these patient’s general health. Sixteen of the patients used drugs in ATC group 
C (cardiovascular drugs), a group that also include drugs for treating hyperlipidemia. The risk 
of high cholesterol- and serum lipid values are five times higher in patients treated with 
olanzapine (Koro et al.). An epidemiological study showed that 7% of 60-year-old people in 
Oslo were treated for high cholesterol levels in year 2000 (Sogaard et al.). In our patient 
group (55-year-old) only five patients (4.6%) were treated with statins. This might indicate 
room for improvement in concomitant drug treatment.  
4.2 Role of CYP450 in metabolism of psychotropics   
 
Pharmaceutical industry has increased their focus on CYP-enzymes in research and 
development of new drugs. Risk of drug interactions and impact on CYP metabolism has 
contributed to avoid new substances that inhibit or modify specific CYP-enzymes. The fact 
that most of the psychotropics are metabolized by CYP-enzymes emphasizes the need for 
knowledge about this enzyme system. Personnel involved in psychopharmacotherapy should 
acquire knowledge about the most important groups of inducers and inhibitors.  
4.3 Use of CYP-genotyping 
 
Only one out of 109 patients had been genotyped prior to the project, indicating that CYP 
genotyping is not performed on a regular basis in this group of patients. The use of CYP-
genotyping is growing in the psychiatric field. Patients in need of long-term antipsychotic 
medication need a well-designed drug regime supported by an initial genotyping. A potential 
lifelong treatment with drugs suggests that an initial genotyping can be cost-effective. 
Pharmacogenetic analyses may contribute to reduce adverse drug reactions and lack of drug 
effect by predicting possible pharmacological pitfalls. The optimal dosing will be highly 
variable among patients depending on genotype. In addition to genetic variability, the 
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situation is made even more complex by environmental factors, other enzyme systems and 
transporters. Today genotyping requires special competence. However the technology has 
been simplified during the recent years. CYP genotyping may contribute to achieve a safer 
and more rational pharmacotherapy. A consensus committee might be required to work out 
guidelines to suggest an optimal use of genotyping and how to interpret information from 
such findings. The cost of genotyping has been considered to be high, but equals only one day 
of hospitalization or one injection of Risperdal Consta® (risperidone administrated every two 
weeks). Poor response of antipsychotic drug treatment and the development of adverse drug 
reactions can lead to patient non-compliance, psychosocial disturbances and poor outcome. 
Cost-effectiveness of TDM and genotyping has not yet been proved in large scale, prospective 
studies. 
4.3.1 CYP-genotype in the patient group compared to the control group 
 
No significant differences were found between the patient group, control group, and allele 
frequencies found in the literature. Schizophrenic patients appear to have the same CYP-
genotype as the Caucasian Norwegian population. The control group differed from the patient 
group in respect to gender and age. These factors were not considered to influence the 
genotype of the population (Schwartz). Poor response or high frequency of side effects in 
pharmacotherapy of psychiatric patients is probably not caused by higher incidence of poor- 
or ultra rapid metabolizer genotype. The frequency of relevant CYP-mutations are high, 40% 
of the patients had a mutation in CYP2D6, the isoenzyme involved in metabolism of 60% of 
the prescribed antipsychotics in this population.  
4.4 Impact of CYP genotype 
 
4.4.1 Ultra rapid metabolizer 
 
Only four patients (3.6%) were positive for the CYP2D6 *2 mutation, coding for gene 
duplication. Three of these patients received treatment with CYP2D6 substrates. However, the 
gene duplication appeared only to have clinical importance in one of the patients, 
demonstrated by sub-therapeutic serum concentrations. The PCR method used in this project 
did not determine the number of active genes, which previous studies have reported to be as 
high as 13 copies (Johansson et al.). The Scandinavian Caucasian population represent one of 
 57
the populations with lowest prevalence of ultra rapid metabolizers (UM) in respect to 
CYP2D6.  
Studies have shown that as much as much as 5.5% of the European population carry the UM 
genotype with the following distribution pattern: 1-2% in Scandinavia; 3.6% in Germany; 7-
10% in Spain, 10% in Italy and Sicily. Studies have further shown an occurrence in Saudi 
Arabians and Ethiopians of 20% and 29% respectively (Bertilsson et al.). With an increasing 
immigration from the Middle East and Africa to the Norwegian society, the share of ultra 
rapid genotype will probably increase over time.   
4.4.2 Poor metabolizers 
 
Five out of 109 patients (4.6%) tested positive for the CYP2D6 poor metabolizer (PM) 
genotype. Our data indicated higher relative exposures of CYP2D6 substrates in the PM 
group. When such a genotype is discovered in a patient, alternative antipsychotics not 
metabolized by CYP2D6 should be considered. An alternative approach is titration with low 
dosing of a CYP2D6 substrate in combination with therapeutic drug monitoring. One of the 
patients in the project with PM-genotype was treated with 0.2 DDD risperidone, resulting in 
serum concentrations corresponding to mid reference range.  
4.4.3 Intermediate metabolizers (heterozygote extensive metabolizers) 
 
Intermediate metabolizers showed slightly higher relative concentration to dose ratios (CD 
1.3) compared to the group extensive metabolizers (normal). This indicates decreased 
CYP2D6 clearance. The variability in the group is high (SD 1), which suggests close follow-
ups of IM genotype patients on pharmacological treatment. Thirty percent of the patients 
(n=33) was intermediate metabolizers for CYP2D6, twenty of these was treated with 
CYP2D6 substrates. IM genotype does not necessarily affect clearance in monotherapy, but 
might be relevant in patients treated with more than one CYP-substrate or concomitant use of 
CYP-inhibitors. This group of heterozygote extensive metabolizers has not been statistically 
explored due to multiple factors influencing the relevance of genotype.  
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4.5 Impact of CYP inhibitors and CYP inducers 
4.5.1 Impact of CYP inhibitors 
 
Use of CYP inhibitors did not change the average serum concentrations of antipsychotic 
treatment in our group. Average dosing of the CYP-inhibitors were low compared to DDD 
and may explain the relative lack of inhibition. Findings in our study do not support that 
levomepromazine and perphenazine are potent inhibitors of CYP2D6 in low doses. 
Yoshimura and coworkers reported that levomepromazine was not a not a relevant CYP-
inhibitor in low doses (Yoshimura, Ueda and Nakamura). Adaptation and regulation of 
enzyme activity might contribute to the low observed relevance of CYP inhibition. No 
differences were found between perphenazine and levomepromazine in relation to CYP- 
inhibition.   
4.5.2 Impact of CYP inducers 
 
Five patients received treatment with the potent CYP-inducer carbamazepine, but only three 
of them were treated with antipsychotics metabolized by isoenzymes prone to induction. One 
of the patients showed a serum concentration far below therapeutic range, and the two other 
patients had twofold relative CD ratios. Drug-to-drug interactions with carbamazepine seemed 
not to be taken into consideration when treatment was decided. Our data suggest that 
treatment with carbamazepine requires close therapeutic drug monitoring of CYP-substrates.  
4.6 Impact of cigarette smoking on CYP1A2 
4.6.1 Impact of smoking on serum concentrations of CYP1A2 substrates 
 
Eighty percent of the patients treated with CYP1A2 substrates (clozapine or olanzapine) 
smoked cigarettes. The minimum consumption was 8 cigarettes daily, indicating induction of 
CYP1A2 by polyaromatic hydrocarbons. The non-smokers had two-fold higher CD ratios of 
CYP1A2 substrates compared to smokers. Our findings are supported by earlier studies 
showing a 2.5 fold higher CD ratios in non-smokers compared to smokers on long term 
clozapine therapy (van der Steijns and van Weelden). Smokers showed 30% decrease in both 
clozapine (2060nmol/L vs. 1406nmol/L) and olanzapine (210nmol/L vs. 147 nmol/L) serum 
concentration. Studies have shown a 20-40% decrease in serum concentration from the same 
dose of clozapine in smokers compared to non-smokers (Meyer); (Seppala et al.).  
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The smokers received higher doses of clozapine and olanzapine than non-smokers. However 
it appears that smoking behavior did not closely correlate to dosing of antipsychotic. This 
raises the question if there is a tendency to underdose smokers and overdose non-smokers, 
since this issue is apparently not a focus in clinical practice. Health care personnel should be 
aware of changes in smoking behavior, which may lead to substantial changes in serum 
concentration of drugs metabolized by isoenzyme CYP1A2 (Zullino et al.). It has been 
suggested that doses of CYP1A2 substrates should be decreased immediately on cessation of 
heavy smoking. A dose reduction of 10% every day until the fourth day was recommended 
together with TDM (Faber and Fuhr). This implies regularly monitoring of smoking behavior 
in patients treated with CYP1A2 substrates.  
 
Another intriguing aspect is the lack of close correlation between number of cigarettes and 
variation in serum concentrations. When comparing different subgroups of smokers, no 
significant differences were found between light and heavy smokers in relation to apparent 
CYP1A2 activity. Regression of the concentration to dose ratio and number of cigarettes 
revealed a Pearson Correlation of –0.11 (p=0.44), which only indicates a minor relationship 
between higher CYP1A2 clearance in heavy compared to light smokers (n=63). For the 
clinician it does not seem crucial to obtain the precise consumption of cigarettes, just establish 
if the patient smokes cigarettes or not. These findings should be further explored due to the 
potential clinical impact and because of a low number of subjects in the non-smoker group.   
 
4.6.2 Individual variability 
 
In this project bivariate correlation barely showed significant connection between daily dosing 
and serum concentrations in clozapine (p=0.042, Pearson 0.36) and olanzapine (p=0.024, 
Pearson 0.35). This confirms that multiple factors are important in predicting the response of 
antipsychotic treatment. The degree of environmental and genetic variability depends on the 
CYP isoenzyme involved. 
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4.7 Use of CYP genotyping and TDM in psychiatry  
 
Studies have shown that the period of untreated schizophrenia is important in the course of the 
disorder. Psychosis and schizophrenia are often untreated for a period of two-three years 
(including the prodromal phase) (Melle et al.). Initial assessments, testing and 
individualization of pharmacological treatment might help decreasing the lag time to 
therapeutic effect. TDM should be performed several times in the establishment and 
adjustment of pharmacological regime. Evaluation of genotyping and TDM-results require 
knowledge about metabolism, enzyme systems and pharmacokinetics. Patient information, 
genotype and serum concentrations have to be interpreted together to obtain valuable 
information. Genotyping alone will not provide this information, but used in combination 
with TDM it might be a step towards individualized medicine. There seems to be a lack of 
knowledge of drug monitoring and genotyping amongst a number of prescribing physicians. 
Increased use of these tools might reduce the current use of “trial and error” practice in 
optimizing psychiatric pharmacological treatment. 
 
4.8 Limitations of the study 
 
The patients were not assessed with diagnostic tools (e.g. PANSS) by the investigators. 
Diagnoses were obtained from patient records deriving from previous or current psychiatric 
hospitals, institutions or nursing homes. The diagnostic work had been performed by a wide 
range of physicians over a long period of time.  
For a number of parameters we found a rather high degree of variability, which made the use 
of advanced statistical tools inappropriate. Small groups with unequal distribution 
complicated the work of detecting possible relationships between clinical factors and 
pharmacotherapy. This led to the descriptive and explorative nature of this study.   
Time from last dose of drug is a crucial factor in measuring serum concentrations. Reference 
ranges are based on trough-values, because the period prior to a new dose shows least amount 
of fluctuations in serum concentrations. Serum concentrations were only measured once, and 
the possibility of non-compliance or variation in the time from last dose cannot be ruled out.  
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4.9 Concluding remarks  
 
Schizophrenic patients on long-term treatment in nursing homes receive today a rather 
comprehensive drug treatment. Polypharmacy both in respect to antipsychotic and 
concomitant medication was common. This group of patients appears to be dosed higher than 
other patients in psychiatric hospitals.  
Multiple factors influence the CYP-activity of the patients; this includes drug-interactions, 
genetic polymorphism and cigarette smoking. All these factors have to be considered in 
psycho-pharmacotherapy. Isolated, certain drug-interactions and intermediate metabolizer 
genotype appeared to be clinically relevant only in some of the patients in our study.  Several 
factors need to be taken into consideration in explanation of serum concentrations from a 
given dose of drug. Genetic and environmental factors have different impact on the different 
CYP isoenzymes. The most important isoenzymes in this group of patients are CYP1A2 and 
CYP2D6. Both of them are relevant in metabolizing antipsychotics in approximately two-
thirds of the patient. CYP2D6 exhibit clinically relevant genetic variation. CYP1A2 does not 
exhibit genetic variations, but is prone to induction from polyaromatic hydrocarbons from 
cigarette smoking. The fact that 75% of these patients smoke cigarettes and 40% carry 
CYP2D6-mutations should emphasize focus on the CYP-system in psychiatry.  
Increased knowledge and availability of CYP-genotyping and therapeutic drug monitoring 
represents an opportunity to reassess the pharmacotherapy of chronically ill schizophrenic 
patients in nursing homes.  
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